1. SAREE AONGSOMWANG Foundation for Consumers, Thailand

2. CCPN Founded 1982, as a coordinating body on health Registered as a Foundation for Consumers, 1996 Non government, non profit ‘no advertising, no bias’ Publishes Smart buyer Magazine and Online ++ Center for Consumers’ interest Campaigns for Policy &Capacity building for consumer organizations 24 staff, 4 paid volunteer & 20 Volunteers Lawyer

3. IN 1994 (Complaint one time is better than complain 1,000 times)

4. Currently FFC has become the leading non-govermental and non- profit organization in Thailand to work directly with consumers and consumer protection policy advocacy. And we will continue to stand side by side with all Thai consumers.

6. CHAPTER [ ] INTELLECTUAL PROPERTY RIGHTS

7. 1. Each Party shall, at a minimum, give effect to this Chapter. International Agreements 2. Further to Article 1, the Parties affirm their existing rights and obligations with respect to each other under the TRIPS Agreement.

8. 3. Each Party shall ratify or accede to the following agreements by the date of entry into force of this Agreement: (a) Patent Cooperation Treaty (1970), as amended in 1979; (b) Paris Convention for the Protection of Industrial Property (1967); (c) Berne Convention for the Protection of Literary and Artistic Works (1971); (d) Convention Relating to the Distribution of Programme-Carrying Signals Transmitted by Satellite (1974); (e) Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks (1989);

9. (f) Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (1977), as amended in 1980; (g) International Convention for the Protection of New Varieties of Plants (1991) (UPOV onvention); (h) Singapore Treaty on the Law of Trademarks (2006); (i) WIPO Copyright Treaty (1996); and (j) WIPO Performances and Phonograms Treaty (1996).

10. 4. Each Party shall notify the WTO of its acceptance of the Protocol amending the TRIPS Agreement done at Geneva on December 6, 2005. 5. Each Party shall make all reasonable efforts ratify or accede to the following agreements by the date of entry into force of the Agreement: (a) Patent Law Treaty (2000); and (b) Hague Agreement Concerning the International Registration of Industrial Designs (1999).

11. Trademarks 1. No Party may require, as a condition of registration, that a sign be visually perceptible, nor may a Party deny registration of a trademark solely on the grounds that the sign of which it is composed is a sound or a scent. 2. Each Party shall provide that trademarks shall include certification marks. Each Party shall also provide that geographical indications are eligible for protection as trademarks.

12. 1. Each Party shall make patents available for any invention, whether a product or process, in all fields of technology, provided that the invention is new, involves an inventive step, and is capable of industrial application. In addition, the Parties confirm that: patents shall be available for any new forms, uses, or methods of using a known product; and a new form, use, or method of using a known product may satisfy the criteria for patentability, even if such invention does not result in the enhancement of the known efficacy of that product.

13. 2. Each Party shall make patents available for inventions for the following: (a) plants and animals, and (b) diagnostic, therapeutic, and surgical methods for the treatment of humans or animals. 3. Each Party may only exclude from patentability inventions, the prevention within its territory of the commercial exploitation of which is necessary to protect ordre public or morality, including to protect human, animal, or plant life or health or to avoid serious prejudice to the environment, provided that such exclusion is not made merely because the exploitation is prohibited by law.

14. 4. Each Party may provide limited exceptions to the exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties. 5. [Placeholder for “Bolar” provision] 6. [Placeholder for provisions concerning patent term restoration/adjustment]

15. 9. Each Party shall provide patent applicants with at least one opportunity to make amendments, corrections, and observations in connection with their applications. Each Party shall permit applicants to make amendments to their patent claims prior to receipt of a first patent office action or communication on the merits. 10. Each Party shall provide that a disclosure of a claimed invention shall be considered to be sufficiently clear and complete if it provides information that allows the invention to be made and used by a person skilled in the art, without undue experimentation, as of the filing date.

16. Pharmaceutical Products 2. [Placeholder for provisions related to data protection for pharmaceutical products] 3. [Placeholder for provisions related to patent linkage] General Provisions 4. [Placeholder for provisions related to patent term/data protection relationship] 5. [Placeholder for definitions of “new pharmaceutical product” and “new agricultural product”]

17. 1. Each Party shall provide that final judicial decisions and administrative rulings of general application pertaining to the enforcement of intellectual property rights shall be in writing and shall state any relevant findings of fact and the reasoning or the legal basis on which the decisions and rulings are based. Each Party shall also provide that such decisions and rulings shall be published16 or, where publication is not racticable, otherwise made available to the public, in its national language in such a manner as to enable governments and right holders to become acquainted with them.

18.  National Budget on Health Care  Access to medicine

19. to compensate the delays by drug registration or in patent granting process Filing date+ 0 Expired date++ 20 years++ Patent term Drug registration (marketing)+ (Jiraporn, 2005)

20. APPLY for PATENT YEAR 0 NO PATENT YEAR DRUG REGISTRATION 1 2 DRUG APPROVED to be in MARKET DATA EXCLUSIVIT Y 5-10 Yrs. 20 PATENT LIFE 20 Yrs. DATA EXCLUSIVIT Y 5-10 Yrs. DRUG REGISTRATION 1818 19 DRUG APPROVED to be in MARKET (Jiraporn, 2005)

21. Rovira model Markov model

22. extension 2 years extension 5 years extension 10 years DE 5 yrs. DE 10 yrs.

23. NEXT 5 yrs DE 5 yrs (81,356) EXT 5 yrs (27,883) DE 5 yrs (233,447) NEXT 30 yrs EXT 5 yrs (619,773)